Printer Friendly

United States : ALITAIR resin-formulated cough product gets NOA.

A notice of allowance (NOA) has been granted by the US Patent and Trademark Office (USPTO) to Alitair Pharmaceuticals' ion exchange resin formulation of benzonatate, a non-narcotic prescription cough product.

The patent includes the potential of the resin-formulated drug in decreasing or eliminating the choking hazard, which is connected with conventional liquid formulations of benzonatate.

Alitair president and CEO William Howard said: "Our oral solid ion exchange resin formulation has been shown to reduce or eliminate the choking hazard.

"Our proprietary technology allows us to bind benzonatate to a resin particle, which represents a completely novel formulation approach and resolves this significant safety issue.

Howard added: "This Notice of Allowance marks an important milestone in our benzonatate product development strategy and may be the key to benzonatate becoming a successful Rx-to-OTC switch candidate."

2012 Al Bawaba (

Provided by an company
COPYRIGHT 2012 Al Bawaba (Middle East) Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2012 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Mena Report
Date:Sep 30, 2012
Previous Article:United States : WIKODA launches new PV TRACKER product.
Next Article:United States : MITSUBISHI ELECTRIC enters into agreement with HDA TRUCK PRIDE.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters